Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neuro-Oncology

Treatment Options and Personalized Care

At a Glance

Leptomeningeal melanoma treatment is personalized according to BRAF mutation status, how quickly symptoms are worsening, overall health, and control of melanoma elsewhere. Options may include immunotherapy, targeted therapy, radiation, clinical trials, and supportive care.

Deciding on a treatment plan for leptomeningeal disease (LMD) requires a specialized, multidisciplinary approach. Because melanoma cells are moving through the fluid around your brain and spine, your care team will likely include neuro-oncologists, radiation oncologists, and your primary melanoma oncologist [1][2]. While LMD is a serious complication, modern therapies have moved us beyond “one-size-fits-all” care toward personalized strategies based on your tumor’s genetics and how you are feeling [3].

Systemic Therapies: The Mainstay of Care

Most treatments for LMD are “systemic,” meaning they travel through your entire body. The choice often depends on how quickly your symptoms are progressing and whether your melanoma has a specific genetic mutation called BRAF V600 [4].

Immunotherapy (Ipilimumab + Nivolumab)

For many patients, the combination of two immunotherapy drugs—ipilimumab and nivolumab—may be considered as a starting point, especially if the disease is not causing immediate, severe symptoms [4].

  • The Goal: These drugs “unleash” your immune system to find and kill cancer cells.
  • The Benefit: Immunotherapy is known for its potential to create durable responses, meaning the cancer may stay under control for a longer period compared to other treatments [5].
  • The Trade-off: It can take weeks or even months for the immune system to fully ramp up. If your symptoms are worsening rapidly, your doctor might choose a faster-acting option first [6]. Safety Warning: Combination immunotherapy can cause serious or delayed immune-related inflammation affecting the bowel, lungs, liver, hormone glands, heart, skin, or nervous system. Contact your oncology team immediately for new or severe symptoms.

Targeted Therapy (BRAF and MEK Inhibitors)

About 50% to 65% of melanomas have a BRAF mutation [7]. If your tumor has this mutation, your doctor may prescribe targeted pills (such as dabrafenib/trametinib or encorafenib/binimetinib) [4].

  • The Goal: These drugs block the specific “engine” driving the cancer’s growth.
  • The Benefit: Targeted therapy often works very quickly, sometimes providing symptom relief within days [6]. This makes it a vital tool if the disease is progressing fast or causing significant pain or weakness [4].
  • The Trade-off: While effective, the cancer often eventually finds a way to “bypass” these drugs, so the responses may not last as long as those from immunotherapy [8]. Safety Warning: These therapies can cause high fevers, rash, diarrhea, eye problems, and heart or liver issues, requiring close monitoring.

The Emerging Role of “Intrathecal” Therapy

Because the blood-brain barrier can block some drugs from reaching the fluid where LMD lives, researchers are exploring intrathecal (IT) therapy—delivering medication directly into the cerebrospinal fluid [9].

IT Nivolumab is an investigational approach. Instead of receiving the drug only through an IV, it is injected directly into the fluid via a lumbar puncture or a specialized port in the head called an Ommaya reservoir [10].

  • Current Evidence: Early trials have shown that this approach is feasible. In one small, selected, nonrandomized study, patients receiving IT nivolumab lived for a median of about 5 months, and some saw much longer benefits, but this does not establish it as a standard of care [10].
  • Availability: This is considered an “investigational” treatment. You may need to join a clinical trial or be at a specialized academic center to access it [11][12]. It carries procedure risks and requires specialist assessment of CSF flow before starting.

Radiation: Targeting the “Bulky” Disease

Radiation is used to treat specific areas of the brain or spine where cancer cells have clumped together into “nodules” or are blocking the flow of fluid [13].

  • Focal Radiation: This is used to treat one specific spot—for example, a spot on the spine causing leg weakness or a spot at the base of the brain affecting your vision [14]. It is highly effective at relieving localized symptoms [13].
  • Whole Brain Radiation Therapy (WBRT): Its role depends heavily on the distribution of your disease, symptoms, and prior treatments. It is used selectively because it can cause significant fatigue and memory issues [14][15].
  • Proton Craniospinal Irradiation (CSI): This is a newer, more precise form of radiation that treats the entire fluid-filled space from the top of the brain to the base of the spine [16]. By using protons instead of traditional X-rays, doctors can spare healthy organs (like the heart and lungs) from unnecessary radiation [17]. While promising, it is not risk-free and is supported by selected studies rather than definitive melanoma-specific evidence [18].

Choosing the Best Path

Your care team will look at several factors to help you choose the right sequence of treatments:

  1. Performance Status: This is a medical term for how well you can perform daily tasks. Patients who are still active and have fewer neurological symptoms often have more treatment options available to them [15][16].
  2. Systemic Control: If the melanoma in the rest of your body (lungs, liver, etc.) is well-controlled, your doctors can focus more aggressively on the LMD [15].
  3. Clinical Trials: Because LMD is a complex condition, clinical trials are often an important option when available, offering access to new drugs and combinations [2].

Treatment for LMD is about disease-directed care working hand-in-hand with palliative and supportive care. Palliative care is not giving up; it is essential for managing pain, nausea, and mood while you receive active treatment [1].

Common questions in this guide

What treatment options are available for leptomeningeal melanoma?
Treatment may include immunotherapy with ipilimumab and nivolumab, BRAF/MEK targeted therapy when the tumor has a BRAF V600 mutation, and radiation for specific areas of disease. Intrathecal treatment, clinical trials, and palliative or supportive care may also be considered. The plan depends on symptoms, how quickly the disease is changing, overall health, and melanoma elsewhere in the body.
How is immunotherapy different from targeted therapy for leptomeningeal disease?
Ipilimumab plus nivolumab helps activate the immune system and may provide durable control, but it can take weeks or months to work fully. BRAF/MEK inhibitors can work quickly, sometimes improving symptoms within days, when the tumor has a BRAF V600 mutation, although the response may not last as long. The care team weighs the speed of the disease, expected benefits, side effects, and the patient's overall health.
Is intrathecal nivolumab a standard treatment for leptomeningeal melanoma?
Intrathecal nivolumab delivers the medicine directly into the cerebrospinal fluid through a lumbar puncture or an Ommaya reservoir. It remains investigational, so access generally requires a clinical trial or specialized center; early studies show that it is feasible but do not establish it as standard care. Specialists also assess cerebrospinal fluid flow and procedure risks before treatment.
When is radiation used for leptomeningeal melanoma?
Focal radiation may treat a localized nodule or blockage that is causing symptoms such as leg weakness or vision problems. Whole-brain radiation is used selectively, while proton craniospinal irradiation may treat the fluid-filled space around the brain and spine in carefully selected situations. The likely benefits and risks depend on the disease pattern, symptoms, and previous treatments.
What factors determine a personalized treatment plan for leptomeningeal melanoma?
Doctors consider the BRAF V600 mutation, how well the patient can manage daily activities, how quickly symptoms are worsening, and whether melanoma elsewhere in the body is controlled. Clinical trial availability and access to specialized centers may also affect the plan. Palliative and supportive care can be provided alongside cancer-directed treatment to manage pain, nausea, mood, and other symptoms.
Which treatment side effects should prompt an urgent call to the oncology team?
New or severe diarrhea, breathing problems, jaundice or other liver concerns, high fever, rash, eye symptoms, heart symptoms, or new neurological changes can signal a serious treatment complication. Combination immunotherapy and BRAF/MEK therapy can both cause delayed or severe side effects. Contact the oncology team promptly rather than waiting for the next appointment.

Get notified when new evidence is published on leptomeningeal melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.

    Wilcox JA, Chukwueke UN, Ahn MJ, et al.

    Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.

    PMID: 38902944
  2. 2

    Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.

    Smalley I, Boire A, Brastianos P, et al.

    Pigment cell & melanoma research 2024; (37(1)):51-67 doi:10.1111/pcmr.13116.

    PMID: 37622466
  3. 3

    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.

    Le Rhun E, Devos P, Weller J, et al.

    Neuro-oncology 2021; (23(7)):1100-1112 doi:10.1093/neuonc/noaa298.

    PMID: 33367859
  4. 4

    Melanoma brain metastases - Interdisciplinary management recommendations 2020.

    Gutzmer R, Vordermark D, Hassel JC, et al.

    Cancer treatment reviews 2020; (89()):102083 doi:10.1016/j.ctrv.2020.102083.

    PMID: 32736188
  5. 5

    Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.

    Brastianos PK, Strickland MR, Lee EQ, et al.

    Nature communications 2021; (12(1)):5954 doi:10.1038/s41467-021-25859-y.

    PMID: 34642329
  6. 6

    Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.

    Sherman WJ, Romiti E, Michaelides L, et al.

    Current treatment options in oncology 2023; (24(12)):1962-1977 doi:10.1007/s11864-023-01155-3.

    PMID: 38158477
  7. 7

    Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.

    Chorti E, Kebir S, Ahmed MS, et al.

    European journal of cancer (Oxford, England : 1990) 2021; (148()):395-404 doi:10.1016/j.ejca.2021.02.016.

    PMID: 33789203
  8. 8

    Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).

    Pedersen S, Johansen EL, Højholt KL, et al.

    European journal of cancer (Oxford, England : 1990) 2025; (217()):115253 doi:10.1016/j.ejca.2025.115253.

    PMID: 39874911
  9. 9

    Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.

    Boire A, Zou Y, Shieh J, et al.

    Cell 2017; (168(6)):1101-1113.e13 doi:10.1016/j.cell.2017.02.025.

    PMID: 28283064
  10. 10

    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

    Glitza Oliva IC, Ferguson SD, Bassett R, et al.

    Nature medicine 2023; (29(4)):898-905 doi:10.1038/s41591-022-02170-x.

    PMID: 36997799
  11. 11

    Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.

    Piña Y, Yadugiri S, Yeboa DN, et al.

    Current oncology reports 2022; (24(1)):43-54 doi:10.1007/s11912-021-01162-3.

    PMID: 35059999
  12. 12

    Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics.

    Faillot M, Goldwirt L, Jouenne F, et al.

    Neurosurgery 2026; (99(4)):882-889 doi:10.1227/neu.0000000000003924.

    PMID: 41636506
  13. 13

    An overview of leptomeningeal disease.

    Nguyen TK, Nguyen EK, Soliman H

    Annals of palliative medicine 2021; (10(1)):909-922 doi:10.21037/apm-20-973.

    PMID: 32921068
  14. 14

    How we treat patients with leptomeningeal metastases.

    Le Rhun E, Preusser M, van den Bent M, et al.

    ESMO open 2019; (4(Suppl 2)):e000507 doi:10.1136/esmoopen-2019-000507.

    PMID: 31231573
  15. 15

    Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.

    Saberian C, Milton DR, Simon J, et al.

    Neuro-oncology practice 2024; (11(4)):452-463 doi:10.1093/nop/npae026.

    PMID: 39006528
  16. 16

    Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.

    Barbour AB, Kotecha R, Lazarev S, et al.

    Advances in radiation oncology 2024; (9(2)):101377 doi:10.1016/j.adro.2023.101377.

    PMID: 38405313
  17. 17

    Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.

    Munir M, Sehrawat K, Hassan H, et al.

    Journal of neuro-oncology 2026; (179(2)).

    PMID: 42667527
  18. 18

    Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.

    Sener U, Webb M, Breen WG, et al.

    Journal of immunotherapy and precision oncology 2024; (7(1)):1-6 doi:10.36401/JIPO-23-20.

    PMID: 38327758

This page is for informational purposes only and does not constitute medical advice. Treatment decisions for leptomeningeal melanoma should be made with your neuro-oncology, radiation oncology, and melanoma care teams.